US4971952A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating inflammation with cartilage inducing factor
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1988-10-27
•
Granted: 1990-11-20
•
Expires: 2008-10-27
Abstract
Abstract Inflammation, acute and/or chronic, is treated with a CIF (TGF-beta). The CIF may be administered locally or systemically, depending upon the indication, and does not require coadministration of activator or cofactor for efficacy.
Inventors
- 👤 Hanne Bentz
- 👤 Larry Ellingsworth
- 👤 Rosa Armstrong
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 17:51
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
64 words
A method of treating a subject for inflammation associated with a graft or transplant, which method comprises: administering an anti-inflammatorily effective amount of a cartilage inducing factor to the subject having a graft or transplant, wherein the cartilage inducing factor is a homodimer whose chains each have or are substantially homologous to the following partial N-terminal amino acid sequence: (a) Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Ley-Gly-Trp-, or (b) Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Ley-Arg-Pro-Leu-Try-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp-.
Claim 2
Independent Claim
64 words
A method of treating a subject for inflammation associated with a graft or transplant, which method comprises: administering an anti-inflammatorily effective amount of a cartilage inducing factor to the subject having a graft or transplant, wherein the cartilage inducing factor is a homodimer whose chains each have or are substantially homologous to the following partial N-terminal amino acid sequence: (a) Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Ley-Gly-Trp-, or (b) Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Ley-Arg-Pro-Leu-Try-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp-.
Claim 3
Dependent Claim
25 words
The method of claim 1 wherein the cartilage inducing factor is a homodimer whose chains each have the amino acid sequence shown in FIG. 1.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein the cartilage inducing factor is substantially free of activating agent or cofactor.
Claim 5
Dependent Claim
25 words
The method of claim 1 wherein the cartilage inducing factor is administered by perfusing the graft or transplant tissue prior to implantation in the subject.
Claim 6
Dependent Claim
13 words
The method of claim 1 wherein the cartilage inducing factor is administered systemically.
Claim 7
Dependent Claim
15 words
The method of claim 1 wherein the cartilage inducing factor is administered by subcutaneous injection.
Claim 8
Independent Claim
58 words
A method of treating a subject for an indication associated with hyperproliferation of erythrocytes or platelets comprising administering an effective amount of a cartilage inducing factor to the subject, wherein the cartilage inducing factor is a homodimer whose chains each have or are substantially homologous to the following partial N-terminal amino acid sequence: (a) Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-, or (b) Ala-Ley-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Ley-Gly-Trp-.
Claim 9
Independent Claim
58 words
A method of treating a subject for an indication associated with hyperproliferation of erythrocytes or platelets comprising administering an effective amount of a cartilage inducing factor to the subject, wherein the cartilage inducing factor is a homodimer whose chains each have or are substantially homologous to the following partial N-terminal amino acid sequence: (a) Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-, or (b) Ala-Ley-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Ley-Gly-Trp-.
Claim 10
Dependent Claim
19 words
The method of claim 7 wherein said indication is selected from the group consisting of polycythemia, thrombocytosis, and splenomegaly.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-11-19 | 1994-05-21 | 1994-11-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-11-19 | 1998-05-21 | 1998-11-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-11-19 | 2002-05-21 | 2002-11-20 | $7700.00 | Window Closed / Lapsed |